Global Artificial Intelligence Clinical Genomics Interpretation Market Projected to Grow at 28.1% CAGR, Reaching $4.68 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Artificial Intelligence Clinical Genomics Interpretation Industry Market Size Be by 2025?
Over recent years, there has been a substantial growth in the market for artificial intelligence in clinical genomics interpretation. Its size is predicted to escalate from $1.35 billion in 2024 to $1.74 billion in 2025, with a compound annual growth rate (CAGR) of 28.5%. The expansion during the historic period is a result of the growing integration of artificial intelligence in healthcare, the escalating demand for tailored medicine, increased availability of genomic data, heightened computational capacity for artificial intelligence algorithms, and a surge in investment in diagnostic tools driven by artificial intelligence.

What's the Long-Term Growth Forecast for the Artificial Intelligence Clinical Genomics Interpretation Market Size Through 2029?
Anticipations are high for substantial expansion in the artificial intelligence clinical genomics interpretation market in the coming years, forecasted to reach $4.68 billion by 2029, growing at a compound annual growth rate (CAGR) of 28.1%. Factors contributing to this projected growth during the forecast period include the increased use of genomics tools powered by artificial intelligence, surging demand for precision medicine, higher incorporation of cloud-based analytics, amplified governmental support for genomics research, and the rising reliance on real-world data in making clinical decisions. Some major future trends encompass advancements in predictive analytics driven by artificial intelligence, innovations in multi-omics data integration, fusion of artificial intelligence with electronic health records, progress in real-time genomic interpretation, and breakthroughs in explainable artificial intelligence for clinical genomics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-clinical-genomics-interpretation-global-market-report

What Are the Key Growth Drivers Fueling the Artificial Intelligence Clinical Genomics Interpretation Market Expansion?
The anticipated surge in demand for personalized medicine is projected to fuel the expansion of the artificial intelligence clinical genomics interpretation market. Personalized medicine is a tailored medical approach that considers the genetic, environmental, and lifestyle factors of a person for diagnosis, treatment, and prevention strategies. The growing interest in personalized medicine stems from its increased effectiveness, as treatments are customized to an individual's genetic profile, enhancing outcomes and mitigating negative effects. AI clinical genomics interpretation contributes to this surge in demand by swiftly evaluating complex genomic data, enabling the identification of precise treatment options that are patient-specific. This enhances the effectiveness of therapy and minimizes experimentation. For instance, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, reported that in 2023, the U.S. Food and Drug Administration (FDA) authorized 16 novel personalized treatments for patients with rare conditions, a noteworthy increase from the six greenlit in 2022. Consequently, the projected increase in demand for personalized medicine is likely to stimulate the growth of the AI clinical genomics interpretation market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28141&type=smp

What Are the Key Trends Driving Artificial Intelligence Clinical Genomics Interpretation Market Growth?
In the artificial intelligence clinical genomics interpretation market, leading companies like QIAGEN are investing in innovative technologies that boost scalability for comprehensive genomic research projects. They aim to facilitate robust data processing, enhance genomic insight precision, and accelerate biomarker and therapeutic target identification. Scalability, in this context, signifies the ability of AI systems to effectively assess large and intricate genomic data without sacrificing speed or precision, an element that's becoming increasingly vital as sequencing volume and complexity escalate. For example, in December 2024, QIAGEN, a biotechnology firm based in Germany, introduced an AI-driven extension for its Ingenuity Pathway Analysis (IPA) platform. This extension automates the interpretation of intricate biological data, and by using AI, it pinpoints crucial genes, pathways, and molecular networks related to diseases. This component also amalgamates QIAGEN's Biomedical Knowledge Base, consisting of several hundreds of millions of relationships derived from AI, thereby facilitating a higher accuracy and more data-centric insights.

How Is the Artificial Intelligence Clinical Genomics Interpretation Market Segmented?
The artificial intelligence clinical genomics interpretation market covered in this report is segmented as

1) By Component: Software, Services
2) By Deployment Mode: Cloud Based, On Premises
3) By Application: Oncology, Rare Diseases, Pharmacogenomics, Infectious Diseases, Other Applications
4) By End User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Other End User

Subsegments:
1) By Software: Genomic Data Analysis, Variant Interpretation, Clinical Decision Support, Predictive Modeling, Reporting And Visualization
2) By Services: Implementation And Integration, Consulting And Advisory, Training And Support, Data Management, Maintenance And Upgrades

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28141&type=smp

Which Companies Are Leading the Charge in Artificial Intelligence Clinical Genomics Interpretation Market Innovation?
Major companies operating in the artificial intelligence clinical genomics interpretation market are F. Hoffmann-La Roche AG, NVIDIA Corporation, Illumina Inc., QIAGEN N.V., Tempus Labs Inc., GeneDx Inc., Freenome Inc., NantHealth Inc., SOPHiA GENETICS SA, Genomenon Inc., DNAnexus Inc., Lifebit Biotech Ltd., Deep Genomics Inc., SpeeDx Pty Ltd, PierianDx Inc., Genuity Science Inc., Karius Inc., FDNA Inc., SeqOne Genomics Inc., Nostos Genomics Inc.

Which Regions Are Leading the Global Artificial Intelligence Clinical Genomics Interpretation Market in Revenue?
North America was the largest region in the artificial intelligence clinical genomics interpretation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence clinical genomics interpretation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28141

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.